%0 Conference Paper
%A Bosch, Iris
%A Lenér, Frida
%A Stankeviciute, Laura
%A Singleton, Ellen Hanna
%A Öhman, Fredrik
%A Quitz, Kajsa
%A Dottori, Maria
%A Berron, David
%A Franzmeier, Nicolai
%A Kern, Silke
%A Zetterberg, Henrik
%A Blennow, Kaj
%A Schöll, Michael
%T From zero to 6,000 in 9 months: Recruitment and innovation strategies for a remote longitudinal Alzheimer's population‐based screening study – Insights from the REAL AD study
%J Alzheimer's and dementia
%V 21
%N Suppl 6
%@ 1552-5260
%M DZNE-2025-01484
%P e106340
%D 2025
%X The REAL AD study aims to validate the diagnostic and prognostic performance of combining blood-based biomarkers and remote cognitive testing as a screening approach for early Alzheimer's disease (AD), leveraging an existing healthcare infrastructure in Western Sweden. Here, we discuss strategies for recruiting a large and representative cohort, demographics and participant retention during the first study phase, and evaluate the process of implementing innovations enabling a fully remote study design.In April 2024, a recruitment campaign was launched in collaboration with a PR company to recruit at least 3000 participants between 50-80 years from the general population. Through an online study platform, participants were enrolled and asked to answer health and lifestyle questionnaires (Step 1), guided to remotely administered cognitive testing (Step 2; using the neotivTrials app or Cognitron battery), and blood sampling at any of the 105 public regional primary care units (Step 3; Figure 1). Additionally, optional remote blood sampling complemented the primary study protocol.At abstract submission, N = 6092 participants (mean age=63.9 years, 70
%B Alzheimer’s Association International Conference
%C 27 Jul 2025 - 31 Jul 2025, Toronto (Canada)
Y2 27 Jul 2025 - 31 Jul 2025
M2 Toronto, Canada
%K Humans
%K Female
%K Male
%K Aged
%K Middle Aged
%K Alzheimer Disease: diagnosis
%K Alzheimer Disease: blood
%K Public Health
%K Aged, 80 and over
%K Biomarkers: blood
%K Sweden
%K Neuropsychological Tests
%K Surveys and Questionnaires
%K Telemedicine
%K Patient Selection
%K Biomarkers (NLM Chemicals)
%F PUB:(DE-HGF)1 ; PUB:(DE-HGF)16
%9 AbstractJournal Article
%$ pmid:41435182
%2 pmc:PMC12726296
%R 10.1002/alz70860_106340
%U https://pub.dzne.de/record/283077